Literature DB >> 2785743

Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro.

J Pfeilschifter1, C Chenu, A Bird, G R Mundy, G D Roodman.   

Abstract

Interleukin-1 (IL-1) alpha and beta and tumor necrosis factor (TNF) alpha and beta are potent stimulators of bone resorption in vitro and in vivo. However, the mechanisms underlying this increased bone resorption have not been clearly defined. Increased bone resorption can result from increased activity of individual osteoclasts, increased numbers of osteoclasts, or both. Therefore, we have used a long-term human marrow culture system that forms multinucleated cells (MNC) with the characteristics of osteoclasts to examine the effects of IL-1 and TNF on osteoclast formation. Human recombinant IL-1 alpha and IL-1 beta, and human recombinant TNF-alpha and TNF-beta stimulated MNC formation from 4- to 60-fold. IL-1 alpha, IL-1 beta, TNF-alpha, and TNF-beta significantly increased MNC formation at very low concentrations: 2.5 x 10(-13) M for IL-1 alpha and IL-1 beta, 10(-11) M for TNF-alpha, and 10(-10) M for TNF-beta In addition, these cytokines enhanced MNC formation in the presence of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], a potent osteotropic factor that stimulates MNC formation by stimulating fusion of mononuclear precursor cells. Simultaneous addition of IL-1 and TNF to the cultures resulted in a synergistic stimulation of MNC formation. These results suggest that: (1) IL-1 and TNF stimulate bone resorption in part by increasing osteoclast formation and (2) an extremely low concentration of these factors can synergistically increase osteoclast formation in the absence of other factors, such as 1,25-(OH)2D3. These data suggest that synergistic interactions among cytokines play an important role in maintaining bone cell activity in normal and pathologic states.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785743     DOI: 10.1002/jbmr.5650040116

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  95 in total

1.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.

Authors:  Y Abu-Amer
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Soluble Tumor Necrosis Factor Alpha Receptor 1, Bone Resorption, and Bone Mineral Density in the Year Following Hip Fractures: The Baltimore Hip Studies.

Authors:  Shabnam Salimi; Michelle Shardell; Ram Miller; Ann L Gruber-Baldini; Denise Orwig; Neal Fedarko; Marc C Hochberg; Jack M Guralnik; Jay Magaziner
Journal:  J Bone Miner Res       Date:  2018-06-15       Impact factor: 6.741

Review 3.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

4.  Is there a causal role for IL-1 in postmenopausal bone loss?

Authors:  R Pacifici
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

5.  Cytokines, hematopoiesis, osteoclastogenesis, and estrogens.

Authors:  S C Manolagas; R L Jilka
Journal:  Calcif Tissue Int       Date:  1992-03       Impact factor: 4.333

6.  Localisation of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity in synovium from patients with inflammatory or degenerative arthritis.

Authors:  B A Ashton; I K Ashton; M J Marshall; R C Butler
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

7.  Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases.

Authors:  A Nemetz; M Tóth; M A García-González; T Zágoni; J Fehér; A S Peña; Z Tulassay
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

8.  Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.

Authors:  R B Kimble; J L Vannice; D C Bloedow; R C Thompson; W Hopfer; V T Kung; C Brownfield; R Pacifici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Proliferative responses to estradiol, IL-1 alpha and TGF beta by cells expressing alkaline phosphatase in human osteoblast-like cell cultures.

Authors:  D J Rickard; M Gowen; B R MacDonald
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

10.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.

Authors:  G Girasole; R L Jilka; G Passeri; S Boswell; G Boder; D C Williams; S C Manolagas
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.